103987-83-3

Basic information

• Product Name: 1-Nitronaphthalene-2-carboxylic acid
• Synonyms: 1-Nitronaphthalene-2-carboxylic acid;1-Nitro-2-Naphthoic Acid
• CAS NO: 103987-83-3
• Molecular Formula: C₁₁H₇NO₄
• Molecular Weight: 217.17758
• Mol File: 103987-83-3.mol

Chemical Properties

• Melting Point: 246 °C
• Boiling Point: 398.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.468±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.40±0.30(Predicted)
• CAS DataBase Reference: 1-Nitronaphthalene-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Nitronaphthalene-2-carboxylic acid(103987-83-3)
• EPA Substance Registry System: 1-Nitronaphthalene-2-carboxylic acid(103987-83-3)

Safety Data

• Hazardous Substances Data: 103987-83-3(Hazardous Substances Data)

Usage

InChI:InChI=1S/C11H7NO4/c13-11(14)9-6-5-7-3-1-2-4-8(7)10(9)12(15)16/h1-6H,(H,13,14)

Upstream product

• 99847-19-5 (1-nitro-[2]naphthyl)-pyruvic acid 
• 872287-19-9 6-hydroxy-5-nitro-benzocyclohepten-7-one 
• 7697-37-2 nitric acid 
• 93-09-4 naphthalene-2-carboxylate 
• 176853-40-0 2-<β-trans-(N,N-dimethylamino)ethenyl>-1-nitronaphthalene 
• 339015-80-4 Dimethyl-[(E)-2-(1-nitro-naphthalen-2-yl)-vinyl]-amine 
• 881-03-8 1-nitro-2-methylnaphthalene 

Downstream Products

• 130956-02-4 1-nitro-[2]naphthoic acid anilide 
• 4919-43-1 1-amino-2-naphthoic acid 
• 78508-71-1 methyl 1-nitro-2-naphthoate 
• 35092-83-2 methyl 1-amino-2-naphthoate 
• 1227924-42-6 1-amino-4-bromo-2-naphthoic acid 
• 1371535-86-2 3-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-6-((6-methylpyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227923-29-6 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one 
• 1227924-49-3 3-((1S,2S)-2-hydroxycyclohexyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[h]quinazolin-4(3H)-one 
• 1227923-94-5 6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-28-8 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methoxypyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-20-0 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 

Relevant articles and documents

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate

Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.

PROCESS FOR MAKING M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease

AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

PROCESS FOR PREPARING SUBSTITUTED AROMATIC CARBOXYLIC ACIDS

A process for preparing an aromatic carboxylic acid having a heteroatom containing substituent is provided that includes reaction in a vessel of an aromatic precursor having an aromatic core with at least one heteroatom containing substituent and at least one hydrogen extending from the core, with a haloacetonitrile under reaction conditions to form an aromatic acetonitrile with an acetonitrile moiety. The aromatic acetonitrile is exposed to an oxidizing agent under conditions to convert the acetonitrile moiety to a carboxylic acid group to prepare the aromatic carboxylic acid having the heteroatom containing substituent.

ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.